[1]许靖,李肖红,秦永德,等.帕金森病脑部葡萄糖代谢和脑多巴胺转运体PET显像特点的临床研究[J].国际放射医学核医学杂志,2016,40(5):338-344.[doi:10.3760/cma.j.issn.1673-4114.2016.05.003]
　Xu Jing,Li Xiaohong,Qin Yongde,et al.Clinical study of brain glucose metabolism and brain dopamine transporter PET imaging in patients with Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):338-344.[doi:10.3760/cma.j.issn.1673-4114.2016.05.003]
点击复制

帕金森病脑部葡萄糖代谢和脑多巴胺转运体PET显像特点的临床研究(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
40
期数:
2016年第5期
页码:
338-344
栏目:
论著
出版日期:
2016-09-25

文章信息/Info

Title:
Clinical study of brain glucose metabolism and brain dopamine transporter PET imaging in patients with Parkinson’s disease
作者:
许靖;  李肖红;  秦永德;  张奇洲;  李毓斌;  刘立水;  谢彬
830011 乌鲁木齐, 新疆医科大学第一附属医院核医学科
Author(s):
Xu Jing;  Li Xiaohong;  Qin Yongde;  Zhang Qizhou;  Li Yubin;  Liu Lishui;  Xie Bin
Department of Nuclear Medicine, the First Affiliated Hospital of Xinjiang Medical University, Wulumuqi 830011, China
关键词:
帕金森病; 葡萄糖; 正电子发射断层显像术; 氟脱氧葡萄糖F18; 多巴胺转运体
Keywords:
Parkinson disease; Glucose; Positron-emission tomography; Fluorodeoxyglucose F18; Dopamine transporter
DOI:
10.3760/cma.j.issn.1673-4114.2016.05.003
摘要:
目的 探讨18F-FDG脑代谢联合11C-甲基-N-2β-甲基酯-3β（4-F苯基）托烷（11C-CFT）脑多巴胺转运体（DAT）PET双显像在帕金森病（PD）诊断与病情严重程度评估中的应用价值。方法 对55例不同严重程度的PD患者及30名健康对照者分别行18F-FDG脑代谢显像和11C-CFT脑DAT PET显像检查，通过勾画ROI，比较PET图像中不同严重程度的PD患者与健康对照者中脑基底节区葡萄糖代谢及DAT分布的差异，分析18F-FDG PET、11C-CFT PET显像在不同严重程度PD评估中的作用及特点。结果 与健康对照者相比，18F-FDG PET显像中PD患者脑葡萄糖代谢改变主要为双侧基底节区壳核对称性代谢增高，同时部分患者伴有大脑皮质不同程度代谢减低；11C-CFT PET显像中PD患者双侧尾状核、壳核前、中、后部表现为DAT分布不同程度减低。单侧症状者或双侧症状者均以患侧对侧基底节区壳核DAT分布减低明显，并以壳核后部DAT分布减低为著。结论 18F-FDG PET联合11C-CFT PET双显像在PD诊断及病情严重程度评估中有应用价值。
Abstract:
Objective To explore 18F-FDG brain metabolism and 11C-2β-carbomethoxy-3β-(4-fluorophenyl) tropane (11C-CFT) brain dopamine transporter(DAT) PET dual imaging in the diagnosis and evaluation of the severity of Parkinson’s disease(PD). Methods Fifty-five patients with different severity of PD and 30 cases of healthy controls were subjected to 18F-FDG cerebral metabolic imaging and 11C-CFT DAT PET imaging examination, in which ROI were outlined to compare the differences in glucose metabolism and DAT distribution in the basal ganglia of PD with different severity among the patients and those of healthy controls based on the PET images. 18F-FDG PET and 11C-CFT PET imaging were used to assess severity of PD. Results By comparison with the healthy controls, 18F-FDG PET imaging indicates that the changes in brain metabolism caused by PD mainly show improvement in symmetry of bilateral basal ganglia putamen. Moreover, some PD cases are accompanied with reduction in the metabolism of cerebral cortex to varying degrees. 11C-CFT PET imaging in PD patients indicates that DAT distribution in their bilateral caudate nucleus, bilateral anterior putamen, medio-putamen, and posterior putamen decreased in different degrees. Based on the symptoms of unilateral or bilateral PD, DAT distribution on the contralateral basal ganglia putamen decreased, whereas posterior putamen DAT distribution decreased more prominently. Conclusion 18F-FDG PET and 11C-CFT PET imaging dual joint inspection has a significant value in diagnosing and assessing the severity of PD.

参考文献/References:

[1] Jankovic J.Parkinson’s disease:clinical features and diagnosis[J].J Neurol Neurosurg Psychiatry, 2008, 79(4):368-376.DOI:10.1136/jnnp.2007.131045.
[2] Kassiou M, Banati R, Holsinger RM, et al.Challenges in molecular imaging of Parkinson’s disease:a brief overview[J].Brain Res Bull, 2009, 78(2/3):105-108.DOI:10.1016/j.brainresbull.2008.08.006.
[3] Eckert T, Eidelberg D.Neuroimaging and therapeutics in movement disorders[J].NeuroRx, 2005, 2(2):361-371.DOI:10.1602/neurorx.2.2.361.
[4] Huang T, Wang H, Tang G, et al.The influence of residualnor-β-CFT in 11C CFT injection on the Parkinson disease diagnosis:a 11C CFT PET study[J].Clin Nucl Med, 2012, 37(8):743-747.DOI:10.1097/RLU.0b013e31824c5fae.
[5] Hughes AJ, Daniel SE, Kilford L, et al.Accuracy of clinical diagnosis of idiopathic Parkinson’s disease:a clinico-pathological study of 100 cases[J].J Neurol Neurosurg Psychiatry, 1992, 55(3):181-184.
[6] 史新冲, 陈玲, 张祥松, 等.帕金森病的脑部葡萄糖代谢特征分析[J].中国神经精神疾病杂志, 2011, 37(9):565-568.DOI:10.3969/j.issn.1002-0152.2011.09.013.Shi CX, Chen L, Zhang XS, et al.Analysis of glucose metabolism in the brain of Parkinson’s disease[J].Chin J Nerv Ment Dis, 2011, 37(9):565-568.
[7] Wichmann T, DeLong MR.Pathophysiology of Parkinson’s disease:the MPTP primate model of the human disorder[J].Ann N Y Acad Sci, 2003, 991(1):199-213.DOI:10.1111/j.1749-6632.2003.tb07477.x.
[8] Arahata Y, Kato T, Tadokoro M, et al.18F-fluorodeoxyglucose positron emission tomography in Parkinson’s disease[J].Nihon Rinsho, 1997, 55(1):222-226.
[9] 潘天虹.多巴胺及多巴胺转运蛋白与帕金森病[J].细胞生物学杂志, 2001, 23(3):166-168.DOI:10.3969/j.issn.1674-7666.2001.03.010.Pan TH.Dopamine and dopamine transporter and Parkinson’s disease[J].Chin J Cell Bio, 2001, 23(3):166-168.
[10] Stiasny-Kolster K, Doerr Y, Moller JC, et al.Combination of ‘idiopathic’ REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT[J].Brain, 2005, 128(Pt 1):126-137.DOI:http://dx.doi.org/10.093/brain/awh322.
[11] 王慧春, 左传涛, 黄喆慜, 等.11C-CFT脑PET显像在早期帕金森病诊断中的临床应用[J].中国临床医学影像杂志, 2010, 21(4):229-232.DOI:10.3969/j.issn.1008-1062.2010.04.001.Wang HC, Zuo CT, Huang ZM, et al.Application of 11C-CFT PET ln the diagnosis of Parkinson’s disease with early-stage[J].J Chin Clin Med Imaging, 2010, 21(4):229-232.
[12] 何婷婷, 王瑞民, 田嘉禾, 等.多巴胺转运蛋白PET成像诊断帕金森病[J].中国医学影像学杂志, 2008, 16(2):94-97.DOI:10.3969/j.issn.1005-5185.2008.02.004.He TT, Wang RM, Tian JH, et al.PET imaging of dopamine transporter(DAT)in the diagnosis of parkinson’s disease[J].Chin J Med Imaging, 2008, 16(2):94-97.
[13] Rinne JO, Ruottinen H, Bergman J, et al.Usefulness of a dopamine transporter PET ligand 18F beta-CFT in assessing disability in Parkinson’s disease[J].J Neurol Neurosurg Psychiatry, 1999, 67(6):737-741.DOI:10.1136/jnnp.67.6.737.
[14] 冼文彪, 史新冲, 张祥松, 等.11C CFT脑多巴胺转运体PET显像对帕金森病诊断和严重程度评估的应用[J].中国神经精神疾病杂志, 2014, 40(8):474-478.DOI:10.3936/j.issn.1002-0152.2014.08.006.Xian WB, Shi XC, Zhang XS, et al.Application of 11C CFT dopamine transporter PET imaging in the diagnosis and severity assessment of Parkinson disease[J].Chin J Nerv Ment Dis, 2014, 40(8):474-478.
[15] Ishibashi K, Oda K, Ishiwata K, et al.Comparison of dopamine transporter decline in a patient with Parkinson’s disease and normal aging effect[J].J Neurol Sci, 2014, 339(1/2):207-209.DOI:10.1016/j.jns.2014.01.015.
[16] Nurmi E, Bergman J, Eskola O, et al.Progression of dopaminergic hypofunction in striatal subregions in Parkinson’s disease using 18F CFT PET[J].Synapse, 2003, 48(3):109-115.DOI:10.1002/syn.10192.
[17] 倪夏珺, 丁正同, 邬剑军, 等.11C-β-CFT脑多巴胺转运体PET显像在帕金森病诊断中的应用[J].中国临床神经科学, 2009, 17(4):371-376.DOI:10.3969/j.issn.1008-0678.2009.04.008.Ni XJ, Ding ZT, Wu JJ.Application of 11C-β-CFT Dopamine Transporter PET Imaging in Diagnosing of Parkinsons Disease[J].Chin J Clin Neurosci, 2009, 17(4):371-376.
[18] Kempster PA, Gibb WR, Stern GM, et al.Asymmetry of substaintianigra neuronal loss in arkinson’s disease and its relevance to the mechanism of levodopa related motor luctuations[J].J Neurol Neumsurg Psychiatry, 1989, 52(1):72-76.
[19] Antonini A, Benti R, De Notaris R, et al.123I-Ioflupane/SPECT binding to striatal dopamine transporter(DAT) uptake in patients with Parkinson’s disease, multiple system atrophy, and progressive supranuclear palsy[J].Neurol Sci, 2003, 24(3):149-150.DOI:10.1007/s10072-003-0103-5.

相似文献/References:

[1]李海峰,张晓军,张锦明.多巴胺转运蛋白显像剂11C-β-CFT在帕金森病中的应用研究[J].国际放射医学核医学杂志,2016,40(3):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
　Li Haifeng,Zhang Xiaojun,Zhang Jinming.Review of the use of dopamine transporter imaging agent 11C-β-CFT for diagnosing Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(5):218.[doi:10.3760/cma.j.issn.1673-4114.2016.03.011]
[2]闫卫红.Raclopride在帕金森病PET中的应用[J].国际放射医学核医学杂志,2005,29(1):27.
　YAN Wei-hong.Application of raclopride PET in Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(5):27.
[3]董爱生,田建明.PET、SPECT及MRS在帕金森病诊断中的应用[J].国际放射医学核医学杂志,2005,29(6):244.
　DONG Ai-sheng,TIAN Jian-ming.The application of PET、SPECT and MRS in Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(5):244.
[4]谭海波,刘兴党.PET在神经干细胞移植治疗帕金森病研究中的进展[J].国际放射医学核医学杂志,2004,28(6):253.
　TAN Hai-bo,LIU Xing-dang.Progress of PET imaging in the study of neural stem cell transplantation treating Parkinson’s disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(5):253.
[5]田季雨.PET在帕金森病病理机制研究中的应用近况[J].国际放射医学核医学杂志,2003,27(2):53.
　TIAN Ji-yu.Recent application of PET in the pathological mechanisms of PD[J].International Journal of Radiation Medicine and Nuclear Medicine,2003,27(5):53.
[6]张海琴.中枢多巴胺转运蛋白显像剂99TcmTRODAT-1[J].国际放射医学核医学杂志,2001,25(3):100.
　ZHANG Hai-qin.99Tcm-TRODAT-1: the central dopamine transporter imaging agent[J].International Journal of Radiation Medicine and Nuclear Medicine,2001,25(5):100.
[7]左传涛.18F—多巴PET在帕金森病中的应用[J].国际放射医学核医学杂志,2000,24(1):4.
　ZUO Chuan-tao.The Applications of 18F-DOPA PET in Parkinson’s Disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(5):4.
[8]孙文善.几种新型的中枢多巴胺转运蛋白显像剂[J].国际放射医学核医学杂志,2000,24(2):62.
　SUN Wen-shan.Several new imaging agents for central dopamine transporter[J].International Journal of Radiation Medicine and Nuclear Medicine,2000,24(5):62.
[9]邓玮玮,张春银.放射性核素显像在帕金森病鉴别诊断中的应用[J].国际放射医学核医学杂志,2017,41(2):132.[doi:10.3760/cma.j.issn.1673-4114.2017.02.010]
　Deng Weiwei,Zhang Chunyin.Application of radionuclide imaging on differential diagnosis of Parkinson disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(5):132.[doi:10.3760/cma.j.issn.1673-4114.2017.02.010]
[10]于江,段玉清,毕常芬,等.多巴胺转运体PET显像剂11C-Altropane的研究进展[J].国际放射医学核医学杂志,2018,(1):74.[doi:10.3760/cma.j.issn.1673-4114.2018.01.014]
　Yu Jiang,Duan Yuqing,Bi Changfen,et al.Progress of dopamine transporter PET imaging agent 11C-Altropane[J].International Journal of Radiation Medicine and Nuclear Medicine,2018,(5):74.[doi:10.3760/cma.j.issn.1673-4114.2018.01.014]

备注/Memo

备注/Memo:
收稿日期:2016-07-01
基金项目:新疆维吾尔自治区科技计划项目(201417101)
通讯作者:秦永德,Email:qyd199013@163.com
更新日期/Last Update: 1900-01-01